Recruitment of patients underway in the phase 2 study of a new treatment for dry eye disease
The first patient has been enrolled in a Phase 2 clinical study evaluating YP-P10 for the treatment of dry eye disease, according to a press release from Yuyu Pharma.
The ICECAP study will include 240 patients at seven US sites and will evaluate the safety, tolerability and efficacy of YP-P10, a new synthetic peptide with anti-inflammatory and healing properties. Earlier this year, the FDA cleared an Investigational New Drug Application for the ophthalmic solution.
According to preclinical data, YP-P10 reduced the production of pro-inflammatory cytokines and chemokines in human peripheral blood mononuclear cells.
“We are delighted to enroll our first patient in ICECAP 1, the Phase 2 clinical study of YP-P10 ophthalmic solution,” Robert You, CEO of Yuyu Pharma, said in the statement. “This is our first
biopharmaceutical clinical trial in the United States, and we are excited
its potential to help DED patients who struggle to find lasting relief with alternatives
therapies currently available on the market.